Wolkin A - Search Results

1

Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia.

Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, Cooper TB, Brodie JD. Wolkin A, et al. Am J Psychiatry. 1989 Jul;146(7):905-8. doi: 10.1176/ajp.146.7.905. Am J Psychiatry. 1989. PMID: 2568094

2

Negative symptoms and hypofrontality in chronic schizophrenia.

Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J. Wolkin A, et al. Arch Gen Psychiatry. 1992 Dec;49(12):959-65. doi: 10.1001/archpsyc.1992.01820120047007. Arch Gen Psychiatry. 1992. PMID: 1360200

3

Importance of pharmacologic control in PET studies: effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia.

Bartlett EJ, Wolkin A, Brodie JD, Laska EM, Wolf AP, Sanfilipo M. Bartlett EJ, et al. Among authors: wolkin a. Psychiatry Res. 1991 Oct;40(2):115-24. doi: 10.1016/0925-4927(91)90003-9. Psychiatry Res. 1991. PMID: 1763142

4

Stability of resting deoxyglucose metabolic values in PET studies of schizophrenia.

Bartlett EJ, Barouche F, Brodie JD, Wolkin A, Angrist B, Rotrosen J, Wolf AP. Bartlett EJ, et al. Among authors: wolkin a. Psychiatry Res. 1991 May;40(1):11-20. doi: 10.1016/0925-4927(91)90025-l. Psychiatry Res. 1991. PMID: 1946838 Free article.

5

Dopamine receptor occupancy and plasma haloperidol levels.

Wolkin A, Brodie JD, Barouche F, Rotrosen J, Wolf AP, Smith M, Fowler J, Cooper TB. Wolkin A, et al. Arch Gen Psychiatry. 1989 May;46(5):482-4. doi: 10.1001/archpsyc.1989.01810050096021. Arch Gen Psychiatry. 1989. PMID: 2785373 No abstract available.

6

Amphetamine response and relapse risk after depot neuroleptic discontinuation.

Angrist B, Peselow E, Rubinstein M, Wolkin A, Rotrosen J. Angrist B, et al. Among authors: wolkin a. Psychopharmacology (Berl). 1985;85(3):277-83. doi: 10.1007/BF00428187. Psychopharmacology (Berl). 1985. PMID: 2860683

7

Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients.

Smith M, Wolf AP, Brodie JD, Arnett CD, Barouche F, Shiue CY, Fowler JS, Russell JA, MacGregor RR, Wolkin A, et al. Smith M, et al. Among authors: wolkin a. Biol Psychiatry. 1988 Apr 1;23(7):653-63. doi: 10.1016/0006-3223(88)90048-0. Biol Psychiatry. 1988. PMID: 2967093

8

Essential fatty acid supplementation in tardive dyskinesia.

Wolkin A, Jordan B, Peselow E, Rubinstein M, Rotrosen J. Wolkin A, et al. Am J Psychiatry. 1986 Jul;143(7):912-4. doi: 10.1176/ajp.143.7.912. Am J Psychiatry. 1986. PMID: 3013033 Clinical Trial.

9

Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography.

Wolkin A, Angrist B, Wolf A, Brodie J, Wolkin B, Jaeger J, Cancro R, Rotrosen J. Wolkin A, et al. Among authors: wolkin b. Psychopharmacology (Berl). 1987;92(2):241-6. doi: 10.1007/BF00177923. Psychopharmacology (Berl). 1987. PMID: 3110848 Clinical Trial.

10

Low frontal glucose utilization in chronic schizophrenia: a replication study.

Wolkin A, Angrist B, Wolf A, Brodie JD, Wolkin B, Jaeger J, Cancro R, Rotrosen J. Wolkin A, et al. Among authors: wolkin b. Am J Psychiatry. 1988 Feb;145(2):251-3. doi: 10.1176/ajp.145.2.251. Am J Psychiatry. 1988. PMID: 3257653

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

132 results

Search Page

Filters